This Must Be the Place and Walgreens Expand Access to Naloxone for Music and Art Lovers Across the Country
Customer-focused approach and continued investments in NARCAN® Nasal Spray supply-readiness efforts help ensure opioid emergency preparedness GAITHERSBURG, Md., Aug. 06, 2024 (GLOBE NEWSWIRE)...
New video and radio segments raise awareness of a potentially life-saving, three-step method that anyone can use to respond in a suspected opioid poisoning GAITHERSBURG, Md., July 24, 2024 (GLOBE...
US FDA declines to approve Orexo`s opioid overdose drug
Naloxone is a medication that rapidly reverses the effects of opioid overdose and is the standard of care for opioid overdose reversal in a community settingNew topline survey findings reinforce the...
Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California
Purdue Pharma L.P. (Purdue) announced that the company has partnered with MMCAP Infuse to provide buprenorphine and naloxone tablets CIII (generic Suboxone), a medication for opioid use disorder (MOUD), at low cost to correctional facilities for incarcerated individuals with opioid use disorder. MMCAP Infuse is a national cooperative group purchasing organization operated by the State of Minnesota, Office of State Procurement, for government facilities that provide healthcare services. Under the agreement, to increase access to treatment for incarcerated individuals, Purdue will provide for distribution approximately 1.25 million tablets at the cost of one penny ($0.01) per tablet.
Drugmaker Amneal agrees to $270 million U.S. opioid settlement
Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose